Medical Marijuana Explosion Continues as Company Agrees to Purchase 83,000 S/F Complex in AZ

Medical Marijuana Explosion Continues as Company Agrees to Purchase 83,000 S/F                                 Complex in AZ  PR Newswire  CORAL SPRINGS, Florida, February 19, 2014  CORAL SPRINGS, Florida, February 19, 2014 /PRNewswire/ --  Alternative care industry sees growth as medical marijuana companies continue expansion: Zoned Properties, Inc. (OTC: ZDPY), Growlife, Inc. (OTCBB: PHOT), Advanced Cannabis Solutions, Inc. (OTCBB: CANN) Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) and GW Pharmaceuticals plc (NASDAQ: GWPH)  Zoned Properties, Inc. (OTC: ZDPY) http://www.zonedproperties.com, a lessor of land, facilities and equipment to the medical marijuana market has entered into a definitive agreement and opened escrow on a multi-tenant industrial complex in Tempe, Arizona. The company is currently in the due diligence period and expects to close on the property within sixty (60) days. The facility has several tenants including a state licensed Arizona medical marijuana cultivator. The 83,000 square foot facility sits on 5.3 acres and is being purchased for $4.6 million.  To read the full press release, please click here:http://www.fnmprofiles.com/profiles-zdpy.html  Newly appointed V.P. of Operations and C.S.O. Bryan McLaren stated "This purchase represents the type of commercial transaction that Zoned Properties, Inc. aspires to accomplish. This property is in the heart of downtown Tempe, Arizona located in very close proximity to Phoenix Sky Harbor Airport as well as many major highways. We believe a purchase like this gives us a great asset base to build off as we continue to execute our strategy of acquiring uniquely zoned properties."  Growlife, Inc. (OTCBB: PHOT) a diversified company operating in the legal cannabis industry which develops, markets and deploys products and services of legal cannabis is pleased to announce that shares sufficient to constitute a quorum under the Company's Bylaws were present either in person or by proxy at the February 7, 2014, special meeting of shareholders and, therefore, the Company transacted business. The preliminary voting results indicate 506,035,500 shares of the common stock of the Company voted in favor of the proposal. This represents 88.2% of the shares entitled to vote on the sole proposed item, which was an amendment of the Company's Certificate of Incorporation increasing the number of shares of common stock the Company is authorized to issue from 1,000,000,000 to 3,000,000,000.  Advanced Cannabis Solutions, Inc. (OTCBB: CANN) recently signed a definitive agreement with Full Circle Capital Corporation, a closed-end investment company.The agreement provides that the investment fund will initially provide $7.5 million to the Company in the form of Senior Secured Convertible Notes, subject to certain conditions.An additional $22.5 million can be borrowed by Company with the mutual agreement of the Company and the investment company. At least 95% of the loan proceeds will be used to acquire properties which the Company, consistent with its business plan, will lease to licensed cannabis growers. The six-year loan will be secured by real estate acquired with the loan proceeds, and will require interest-only payments at a rate of 12% per year.  Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of NORTHERA^[^TM^](droxidopa)for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH. NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic NOH caused by primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.  GW Pharmaceuticals plc (NASDAQ: GWPH) a biopharmaceutical company, together with its subsidiaries, is engaged in discovering, developing, and commercializing cannabinoid prescription medicines. The company operates through three segments: Sativex Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company's product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd.On Tuesday, GWPH closed down 1.66% on over 300 thousand shares traded.  FinancialNewsMedia.comis leading provider of third party publishing &news dissemination services. If you would like more information regarding our news coverage solutions, please visithttp://www.financialnewsmedia.comfor more details. Get an edge on the market with ourPremium News Alertsthat are FREE for a limited time athttp://www.financialnewsmedia.com/. Follow us on Facebook:http://www.facebook.com/financialnewsmediaand Twitter:http://twitter.com/FNMgroup.   DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand dollars for news coverage of the current press release issued by Zoned Properties, Inc. by the company.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.   This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.  Contact Information: Company: FN Media Group, LLC Contact email: editor@financialnewsmedia.com U.S. Phone: 1(954)345-0611 URL: http://www.financialnewsmedia.com  SOURCE FN Media Group LLC  
Press spacebar to pause and continue. Press esc to stop.